Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | hypothetical protein | 0.0111 | 0.2689 | 0.3911 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.034 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0188 | 0.515 | 1 |
Entamoeba histolytica | DNA repair and recombination protein, putative | 0.0188 | 0.515 | 0.5 |
Leishmania major | mitochondrial DNA polymerase beta-PAK, putative | 0.0161 | 0.4281 | 0.4281 |
Plasmodium vivax | DNA polymerase alpha, putative | 0.005 | 0.0736 | 0.5 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF6 | 0.0188 | 0.515 | 0.515 |
Schistosoma mansoni | hypothetical protein | 0.0093 | 0.2119 | 0.2502 |
Entamoeba histolytica | hypothetical protein, conserved | 0.0188 | 0.515 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0179 | 0.4861 | 0.5 |
Schistosoma mansoni | DNA polymerase gamma | 0.0111 | 0.2689 | 0.3911 |
Trypanosoma cruzi | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Echinococcus granulosus | DNA polymerase subunit gamma | 0.0111 | 0.2689 | 0.3911 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0027 | 0.0003 | 0.0003 |
Echinococcus multilocularis | ATP dependent DNA helicase PIF1 | 0.0188 | 0.515 | 1 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.034 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0161 | 0.4281 | 0.4281 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0058 | 0.1003 | 0.1003 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF7 | 0.0188 | 0.515 | 0.515 |
Loa Loa (eye worm) | hypothetical protein | 0.0111 | 0.2689 | 1 |
Brugia malayi | DNA polymerase I family protein | 0.0111 | 0.2689 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.0093 | 0.2119 | 0.2119 |
Echinococcus granulosus | ATP dependent DNA helicase PIF1 | 0.0188 | 0.515 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0055 | 0.0893 | 1 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF6, putative | 0.0188 | 0.515 | 0.515 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0188 | 0.515 | 0.515 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0188 | 0.515 | 1 |
Onchocerca volvulus | DNA polymerase alpha catalytic subunit homolog | 0.0084 | 0.1843 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0048 | 0.0669 | 0.0669 |
Trypanosoma brucei | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0027 | 0.0003 | 0.0003 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.0027 | 0.0003 | 0.0003 |
Giardia lamblia | Rrm3p helicase | 0.0188 | 0.515 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0027 | 0.0003 | 0.0003 |
Trypanosoma cruzi | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Mycobacterium ulcerans | hypothetical protein | 0.0179 | 0.4861 | 0.5 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0161 | 0.4281 | 0.4281 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.034 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0027 | 0.0003 | 0.0003 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.